Novartis provided a peek Saturday of how it might expand development of its experimental drug remibrutinib, a BTK inhibitor being tested in a range of immunology and neurology conditions.
In a platform trial examining five compounds in the chronic skin condition hidradenitis suppurativa, remibrutinib met its primary endpoint at both dose levels. The data are early, as only 66 patients received remibrutinib, split evenly between the 25 mg and 100 mg doses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.